HCV New Drugs

Patients with hepatitis C have an increased risk for disease progression to cirrhosis and potentially hepatocellular carcinoma. Recent studies have focused on defining liver cancer risks related to HCV progression and the rates of liver cancer after HCV clearance with new direct-acting antivirals.

The following include several recent that refute previous data suggesting that DAA therapy may increase the risk for liver cancer. Rather, researchers have found it more likely that any increased risk for HCC after DAA therapy is linked to baseline risk factors. Additional include data on liver cancer incidence among patients with comorbidities.

Continue reading: https://www.healio.com/hepatology/oncology/news/online/%7B967349fa-e7ca-4c21-9062-95e966a7f7d1%7D/8-reports-on-liver-cancer-outcomes-with-hcv-daa-therapy